"Management maintained an appropriately measured view into Phase 3 REMARC data for Revlimid, which we believe is appropriate given the cooperative group nature of the study. Importantly, REMARC is one of five Revlimid + Rituxan or R2 studies in Lymphoma, and any potential shortcomings for REMARC would not necessarily be translatable to the other four Celgene-sponsored studies. Importantly, we note that Revlimid is already used off label in the US in NHL, suggesting only upside from the results of REMARC," wrote Canaccord.
According to the analysts, the company's management maintained a positive view for Otezlas value proposition and "pre-biologic" positioning and acknowledged that this paradigm may ultimately extend beyond psoriasis. The analyst believes any indication where Otezla shows meaningful efficacy vs. a biologic alternative represents upside due to lower pricing and oral dosing.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.